This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
<div>AbstractPurpose:<p>Tumor growth rate (TGR) represents the percentage change in tumor volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR<sub>3m</sub>) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in neuroendocrine tumors (NET).</p>Experimental Design:<p>Patients from 7 centers with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST/WW were eligible. Computed tomography (CT)/MRI performed at prebaseline, baseline, and 3(±1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR<sub>3m-BL</sub>; paired <i>T</i> test), and Aim-2: validate TGR<sub>3m</sub> (<0.8%/m vs. ≥0.8%/m) as an early biomarker in an independent cohort (Kaplan–Meier/Cox regression).</p>Results:<p>Of 785 patients screened, 127 were eligible. Mean (SD) TGR<sub>0</sub> and TGR<sub>3m</sub> were 5.4%/m (14.9) and −1.4%/m (11.8), respectively. Mean (SD) ΔTGR<sub>3m-BL</sub> paired-difference was −6.8%/m (19.3; <i>P</i> < 0.001). Most marked ΔTGR<sub>3m-BL</sub> [mean (SD)] were identified with targeted therapies [−11.3%/m (4.7); <i>P</i> = 0.0237] and chemotherapy [−7.9%/m (3.4); <i>P</i> = 0.0261]. Multivariable analysis confirmed the absence of previous treatment (OR = 4.65; 95% CI, 1.31–16.52; <i>P</i> = 0.018) and low TGR<sub>3m</sub> (continuous variable; OR 1.09; 95% CI, 1.01–1.19; <i>P</i> = 0.042) to be independent predictors of radiologic objective response. When the multivariable survival analysis for PFS (Cox regression) was adjusted to grade (<i>P</i> = 0.004) and stage (<i>P</i> = 0.017), TGR<sub>3m</sub> ≥ 0.8 (vs. <0.8) maintained its significance as a prognostic factor (<i>P</i> < 0.001), whereas TGR<sub>0</sub> and ΔTGR<sub>3m-BL</sub> did not. TGR<sub>3m</sub> ≥ 0.8%/m was confirmed as an independent prognostic factor for PFS [external validation; Aim-2; multivariable HR 2.21 (95% CI, 1.21–3.70; <i>P</i> = 0.003)].</p>Conclusions:<p>TGR has a role as a biomarker for monitoring response to therapy for early identification of treatment-induced changes and for early prediction of PFS and radiologic objective response.</p></div>
<div>AbstractPurpose:<p>Tumor growth rate (TGR) represents the percentage change in tumor volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR<sub>3m</sub>) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in neuroendocrine tumors (NET).</p>Experimental Design:<p>Patients from 7 centers with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST/WW were eligible. Computed tomography (CT)/MRI performed at prebaseline, baseline, and 3(±1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR<sub>3m-BL</sub>; paired <i>T</i> test), and Aim-2: validate TGR<sub>3m</sub> (<0.8%/m vs. ≥0.8%/m) as an early biomarker in an independent cohort (Kaplan–Meier/Cox regression).</p>Results:<p>Of 785 patients screened, 127 were eligible. Mean (SD) TGR<sub>0</sub> and TGR<sub>3m</sub> were 5.4%/m (14.9) and −1.4%/m (11.8), respectively. Mean (SD) ΔTGR<sub>3m-BL</sub> paired-difference was −6.8%/m (19.3; <i>P</i> < 0.001). Most marked ΔTGR<sub>3m-BL</sub> [mean (SD)] were identified with targeted therapies [−11.3%/m (4.7); <i>P</i> = 0.0237] and chemotherapy [−7.9%/m (3.4); <i>P</i> = 0.0261]. Multivariable analysis confirmed the absence of previous treatment (OR = 4.65; 95% CI, 1.31–16.52; <i>P</i> = 0.018) and low TGR<sub>3m</sub> (continuous variable; OR 1.09; 95% CI, 1.01–1.19; <i>P</i> = 0.042) to be independent predictors of radiologic objective response. When the multivariable survival analysis for PFS (Cox regression) was adjusted to grade (<i>P</i> = 0.004) and stage (<i>P</i> = 0.017), TGR<sub>3m</sub> ≥ 0.8 (vs. <0.8) maintained its significance as a prognostic factor (<i>P</i> < 0.001), whereas TGR<sub>0</sub> and ΔTGR<sub>3m-BL</sub> did not. TGR<sub>3m</sub> ≥ 0.8%/m was confirmed as an independent prognostic factor for PFS [external validation; Aim-2; multivariable HR 2.21 (95% CI, 1.21–3.70; <i>P</i> = 0.003)].</p>Conclusions:<p>TGR has a role as a biomarker for monitoring response to therapy for early identification of treatment-induced changes and for early prediction of PFS and radiologic objective response.</p></div>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.